Does Emgality Work for Cluster Headaches?
No, Emgality (galcanezumab) does not work for cluster headaches and is not approved for them. The FDA approved it in 2018 solely for episodic migraine prevention in adults.[1] Clinical trials focused exclusively on migraine patients; it showed no benefit in cluster headache studies.[2]
What Do Trials Show for Cluster Headaches?
Two key phase 3 trials tested galcanezumab in episodic cluster headache patients who failed other preventives. The primary endpoint—reduction in weekly attack frequency from baseline to weeks 1-3—failed in both. One trial (CGAB) saw a mean reduction of 12.8 attacks per week on drug vs. 11.0 on placebo (not statistically significant). The other (CGAJ) had similar non-significant results.[3][4] Galcanezumab did shorten individual attacks slightly but did not reduce their frequency or duration enough to meet efficacy thresholds.
Why Doesn't It Work for Cluster Despite Migraine Success?
Cluster headaches differ mechanistically from migraines. Emgality blocks CGRP, a key migraine pathway, but cluster involves the trigeminal-autonomic reflex and hypothalamus more prominently. Migraine trials cut monthly headache days by 4-5 vs. placebo; cluster trials missed this mark entirely.[2][5] CGRP blockers like Emgality succeed in migraine (50% response rate) but fail in most cluster studies.
What Treatments Work for Cluster Headaches Instead?
Acute attacks: High-flow oxygen (12 L/min for 15 minutes, 70-80% effective) or sumatriptan injections/nasal spray.[6]
Prevention: Verapamil (first-line, 240-960 mg/day), corticosteroids (short-term bridge), or galcanezumab alternatives like Emgality—no, wait, others like fremanezumab failed too, but Emgality's cousin erenumab has mixed data. Top options remain verapamil, lithium, or topiramate. For refractory cases, occipital nerve blocks or neuromodulation devices like gammaCore.[6][7]
Is Anyone Still Prescribing Emgality Off-Label for Cluster?
Rarely. Some neurologists tried it post-migraine approval due to CGRP overlap, but trial failures curbed this. A few case reports note partial relief in chronic cluster, but no large-scale evidence supports it. Guidelines (American Headache Society) do not recommend CGRP monoclonal antibodies for cluster.[8]
Any Ongoing Research or Patent Details?
No active phase 3 trials for cluster; focus shifted back to migraine. Emgality's key U.S. patent (composition of matter) expires around 2033, per DrugPatentWatch.[9] Eli Lilly holds it—no cluster-related exclusivities.
[1] FDA Approval Letter for Emgality, 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf
[2] Lancet Neurology, 2020: "Galcanezumab in episodic cluster headache."
[3] New England Journal of Medicine, 2020 (CGAB trial).
[4] New England Journal of Medicine, 2020 (CGAJ trial).
[5] Eli Lilly ClinicalTrials.gov summaries (NCT02397473, NCT02438826).
[6] American Headache Society Position Statement on Cluster Headache, 2021.
[7] Cephalalgia Guidelines, 2022.
[8] AHS Guidelines Update, 2023.
[9] DrugPatentWatch.com: Emgality Patents. https://www.drugpatentwatch.com/p/tradename/EMGALITY